GeneDx Holdings Corp vs Block Inc — how do they compare? GeneDx Holdings Corp trades at $82.98 (market cap $2.44B), while Block Inc trades at $78.31 (market cap $47.50B). The key difference: Block Inc is far larger — about 19.5× GeneDx Holdings Corp's market cap, and Block Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| WGS | XYZ | |
|---|---|---|
Market Cap | $2.44B | $47.50B |
Sector | Technology | Technology |
52-Week High | $167.51 | $84.64 |
52-Week Low | $34.51 | $49.04 |
Enterprise Value | $2.48B | $42.41B |
Signals from Pluang's Aura AI — not financial advice
GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.
Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.
XYZ trades at $77.97, down 1.28% on the day, with strong analyst support (75% buy ratings) and a $99.47 consensus price target. The stock shows bullish technical momentum with recent earnings beats in Q1 and Q2 2026, including Q2 EPS of $1.02 beating $0.871 estimates. Revenue reached $24.19B in 2025, though net margins remain thin at 1.43%. Recent news highlights Square's expanded credit card features and AI integration driving operational efficiency.
Outlook remains positive with raised 2026 guidance and 25% gross profit growth, though high P/E of 141.2 signals premium valuation. Key risks include competitive fintech pressure and execution on AI initiatives. Institutional buying and strong Cash App performance support upside potential toward price targets.
Trailing returns across standard periods
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →